Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 10/20 | 0.52 |
| ▸ | CALCR | P30988 | 3/20 | 0.51 |
| ▸ | APLNR | P35414 | 1/20 | 0.51 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSH | P09668 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506916 | 0.88 | APLNR (0.52) | CXCL8CALCRAPLNRCRHR1CRHR2 | |
| SCHEMBL29634967 | 0.86 | MAPK8 (0.49) | CALCRAPLNRF2 | |
| SCHEMBL26373782 | 0.84 | CTSL (0.49) | CXCL8CALCRAPLNRCRHR1CRHR2 | |
| SCHEMBL29635007 | 0.81 | APLNR (0.52) | CALCRAPLNRCRHR1CRHR2CTSL | |
| SCHEMBL30262190 | 0.81 | APLNR (0.53) | CALCRAPLNRCTSLCTSHCTSS | |
| SCHEMBL31050544 | 0.81 | CTSL (0.53) | CXCL8APLNRF2CTSLCTSH | |
| SCHEMBL29675066 | 0.81 | MC4R (0.56) | CALCRAPLNRCRHR1CRHR2CTSL | |
| SCHEMBL26374256 | 0.81 | CTSL (0.48) | CXCL8CALCRAPLNRCRHR1CRHR2 | |
| SCHEMBL29934240 | 0.81 | APLNR (0.61) | CALCRAPLNRCTSLCTSHCTSS | |
| SCHEMBL14050018 | 0.80 | SLC6A2 (0.54) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955620-A | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118930608-A | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-114341158-B | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2024-08-06 | — | — | CN | disclosed |
| EP-4274835-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2023-11-15 | — | — | EP | disclosed |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-10-06 | — | — | US | disclosed |
| WO-2022148843-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-07-14 | — | — | WO | disclosed |
| CN-114341158-A | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | CXCL8 328/4885CALCR 1471/4885APLNR 500/4885 |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | CXCL8 328/4885CALCR 1471/4885APLNR 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.